Effects of SmofKabiven® E, a nutrition solution given into the vein, in lung cancer patients

Registry ID

EUCTR2017-001559-30

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE4

Sponsor

Fresenius Kabi Deutschland GmbH

Start date

2017-08-30

Completion date

2019-04-05

Last update

2026-08-16

Conditions

• Metastatic Non-Small Cell Lung Cancer

Summary

The primary objective of the study is to show superiority in efficacy indicated by change in total body weight, of long-term PN with SmofKabiven E in addition to oral nutrition according to standard of care (test group) over oral nutrition as per standard of care alone (control group) during chemo- and/or immunotherapy.

Locations

• , , France

Related clinical trials

• A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
• Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
• Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer

View on source registry